Your browser doesn't support javascript.
loading
Endoscopic full-thickness resection of T1 colorectal cancers: a retrospective analysis from a multicenter Dutch eFTR registry.
Zwager, Liselotte W; Bastiaansen, Barbara A J; van der Spek, Bas W; Heine, Dimitri N; Schreuder, Ramon M; Perk, Lars E; Weusten, Bas L A M; Boonstra, Jurjen J; van der Sluis, Hedwig; Wolters, Hugo J; Bekkering, Frank C; Rietdijk, Svend T; Schwartz, Matthijs P; Nagengast, Wouter B; Ten Hove, W Rogier; Terhaar Sive Droste, Jochim S; Rando Munoz, Francisco J; Vlug, Marije S; Beaumont, Hanneke; Houben, Martin H M G; Seerden, Tom C J; de Wijkerslooth, Thomas R; Gielisse, Eric A R; Hazewinkel, Yark; de Ridder, Rogier; Straathof, Jan-Willem A; van der Vlugt, Manon; Koens, Lianne; Fockens, Paul; Dekker, Evelien.
Afiliação
  • Zwager LW; Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, location AMC, Amsterdam Gastroenterology & Metabolism, University of Amsterdam, Amsterdam, the Netherlands.
  • Bastiaansen BAJ; Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, location AMC, Amsterdam Gastroenterology & Metabolism, University of Amsterdam, Amsterdam, the Netherlands.
  • van der Spek BW; Department of Gastroenterology and Hepatology, Noordwest Hospital Group, Alkmaar, the Netherlands.
  • Heine DN; Department of Gastroenterology and Hepatology, Noordwest Hospital Group, Alkmaar, the Netherlands.
  • Schreuder RM; Department of Gastroenterology and Hepatology, Catharina Hospital, Eindhoven, the Netherlands.
  • Perk LE; Department of Gastroenterology and Hepatology, Haaglanden Medical Center, the Hague, the Netherlands.
  • Weusten BLAM; Department of Gastroenterology and Hepatology, St. Antonius Hospital, Nieuwegein, the Netherlands.
  • Boonstra JJ; Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, the Netherlands.
  • van der Sluis H; Department of Gastroenterology and Hepatology, Isala Clinics, Zwolle, the Netherlands.
  • Wolters HJ; Department of Gastroenterology and Hepatology, Martini Hospital, Groningen, the Netherlands.
  • Bekkering FC; Department of Gastroenterology and Hepatology, IJsselland Hospital, Capelle aan den IJssel, the Netherlands.
  • Rietdijk ST; Department of Gastroenterology and Hepatology, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands.
  • Schwartz MP; Department of Gastroenterology and Hepatology, Meander Medical Center, Amersfoort, the Netherlands.
  • Nagengast WB; Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Ten Hove WR; Department of Gastroenterology and Hepatology, Alrijne Medical Group, Leiden, the Netherlands.
  • Terhaar Sive Droste JS; Department of Gastroenterology and Hepatology, Jeroen Bosch Hospital, Den Bosch, the Netherlands.
  • Rando Munoz FJ; Department of Gastroenterology and Hepatology, Nij Smellinghe Hospital, Drachten, the Netherlands.
  • Vlug MS; Department of Gastroenterology and Hepatology, Dijklander Hospital, Hoorn, the Netherlands.
  • Beaumont H; Department of Gastroenterology and Hepatology, Amsterdam University Medical Center, location VU, Amsterdam, the Netherlands.
  • Houben MHMG; Department of Gastroenterology and Hepatology, Haga Teaching Hospital, the Hague, the Netherlands.
  • Seerden TCJ; Department of Gastroenterology and Hepatology, Amphia Hospital, Breda, the Netherlands.
  • de Wijkerslooth TR; Department of Gastroenterology and Hepatology, Antoni van Leeuwenhoek Hospital (NKI /AVL), Amsterdam, the Netherlands.
  • Gielisse EAR; Department of Gastroenterology and Hepatology, Rode Kruis Hospital, Beverwijk, the Netherlands.
  • Hazewinkel Y; Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • de Ridder R; Department of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht, the Netherlands.
  • Straathof JA; Department of Gastroenterology and Hepatology, Maxima Medical Center, Eindhoven, the Netherlands.
  • van der Vlugt M; Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, location AMC, Amsterdam Gastroenterology & Metabolism, University of Amsterdam, Amsterdam, the Netherlands.
  • Koens L; Department of Pathology, Amsterdam University Medical Centers, location AMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Fockens P; Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, location AMC, Amsterdam Gastroenterology & Metabolism, University of Amsterdam, Amsterdam, the Netherlands.
  • Dekker E; Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, location AMC, Amsterdam Gastroenterology & Metabolism, University of Amsterdam, Amsterdam, the Netherlands.
Endoscopy ; 54(5): 475-485, 2022 05.
Article em En | MEDLINE | ID: mdl-34488228
BACKGROUND: Complete endoscopic resection and accurate histological evaluation for T1 colorectal cancer (CRC) are critical in determining subsequent treatment. Endoscopic full-thickness resection (eFTR) is a new treatment option for T1 CRC < 2 cm. We aimed to report clinical outcomes and short-term results. METHODS: Consecutive eFTR procedures for T1 CRC, prospectively recorded in our national registry between November 2015 and April 2020, were retrospectively analyzed. Primary outcomes were technical success and R0 resection. Secondary outcomes were histological risk assessment, curative resection, adverse events, and short-term outcomes. RESULTS: We included 330 procedures: 132 primary resections and 198 secondary scar resections after incomplete T1 CRC resection. Overall technical success, R0 resection, and curative resection rates were 87.0 % (95 % confidence interval [CI] 82.7 %-90.3 %), 85.6 % (95 %CI 81.2 %-89.2 %), and 60.3 % (95 %CI 54.7 %-65.7 %). Curative resection rate was 23.7 % (95 %CI 15.9 %-33.6 %) for primary resection of T1 CRC and 60.8 % (95 %CI 50.4 %-70.4 %) after excluding deep submucosal invasion as a risk factor. Risk stratification was possible in 99.3 %. The severe adverse event rate was 2.2 %. Additional oncological surgery was performed in 49/320 (15.3 %), with residual cancer in 11/49 (22.4 %). Endoscopic follow-up was available in 200/242 (82.6 %), with a median of 4 months and residual cancer in 1 (0.5 %) following an incomplete resection. CONCLUSIONS: eFTR is relatively safe and effective for resection of small T1 CRC, both as primary and secondary treatment. eFTR can expand endoscopic treatment options for T1 CRC and could help to reduce surgical overtreatment. Future studies should focus on long-term outcomes.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Ressecção Endoscópica de Mucosa Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Ressecção Endoscópica de Mucosa Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article